Abstract Organic anion transporting polypeptides (OATPs) are polyspecific organic anion transporters, which are expressed in the blood-brain barrier, the choroid plexus, and other organs. The physiologic function of OATPs in extrahepatic tissues remains ambiguous. In rat retina, members of the OATP family are expressed. We therefore investigated the human retina for the expression of OATP1A2 and OATP2B1 and extended the study to human brain. Furthermore, we searched for peptide neurotransmitters as novel OATP substrates. OATP1A2 displayed a broad expression pattern in human retina as assessed by immunofluorescence localization. It is expressed in photoreceptor bodies and somas of amacrine cells. OATP1B2 expression is restricted to the inner nuclear layer and to the inner plexiform layer. Using paraffin sections from human cortex, cerebellum, and hippocampus, OATP1A2 was localized to neurons and neuronal processes, while OATP2B1 is expressed in endothelial cells of brain capillaries. Substance P and vasoactive intestinal peptide were identified as substrates for OATP1A2 and OATP2B1. Doublelabeling immunofluorescence of human retina demonstrated the presence of substance P and of vasoactive intestinal peptides in neurons expressing OATP1A2 and OATP2B1, respectively. The expression of OATP1A2 and OATP2B1 in retinal neurons implies a role of these transporters in the reuptake of peptide neurotransmitters released from retinal neurons. The abundant expression of OATP1A2 in brain neurons points to the possibility that OATP1A2 could be involved in the homeostasis of neurosteroids. The high expression of OATP2B1 in brain capillaries supports an important function of OATPs in substance penetration across the blood-brain barrier.
Introduction
Organic anion transporting polypeptides (humans, OATPs; rodents, rOATPs) represent an important group of transporters with a wide spectrum of amphipathic substrates [21, 33] . Initially, OATPs were isolated from liver and localized to the basolateral membrane of hepatocytes, where they mediate sodium-independent transport of bile salts and cholephilic anionic compounds. To date, dozens of family members, including 16 in rat, 15 in mouse, and 11 in human, have been identified. They are expressed in many organs including the kidney, placenta, brain, and retina (Table 1) [20, 22, 33] . Besides bile salts, they transport a wide range of endogenous and exogenous compounds, such as steroid hormones and their conjugates, thyroid hormones, prostaglandins, small peptides, and numerous drugs [20, 22] . Yet, the physiological functions of these transporters in extrahepatic organs remain ambiguous. Since many members are expressed in cells that constitute barriers limiting the exchange of solutes between compartments, e.g., blood-brain barrier, choroid plexus epithelium, and testis, it is believed that OATPs play a role in maintaining tissue homeostasis, bioavailability, and disposition of numerous drugs [20, 30, 65] .
In rat retina, rOATP1A4 and rOATP1A5 have been identified. rOATP1A4 has been localized in the apical region of the retinal pigment epithelium (RPE) [15] and rOATP1A5 in the ganglion and inner nuclear cell layers [28] . Although their distinct functions in the retina remain to be established, evidence that rOATP1A4-mediated transport activities could be competitively inhibited by the N-retinyl-N-retinylidene ethanolamine, an unusual retinoid implicated in the age-related visual impairment [62] , suggests that this transporter is involved in accumulating this harmful retinoid in the RPE [15] . Despite their potential significance in retinal pathogenesis, it is so far not clear whether OATPs are expressed in human retina.
Therefore, we aimed to investigate the expression of OATPs in human retina. We analyzed OATP1A2 and OATP2B1 in the present study, as they are very likely expressed in the retina for several reasons. First, OATP1A2 is classified with rOATP1A4 and rOATP1A5 in the rOATP1A/OATP1A subfamily [21] and, thus, closely related to the rat OATPs expressed in the retina. Second, these two OATPs are abundantly expressed in the brain [35, 36] . It is well known that many brain-expressed neurotransmitter transporters are also expressed in the retina [6] . Finally, OATP1A2 and OATP2B1 display strong expression in the ocular ciliary body epithelium [13] , a tissue with which retina is anatomically connected and has a common embryonic origin. Previously, we have reported the expression of OATP1A2 in brain capillary endothelium [12] , but the cellular localization of OATP2B1 was not determined. Given the expression of neurotransmitter transporters in the retina and brain, we included human brain into the localization studies. Finally, we searched for physiologic substrates pertinent to the cell typespecific expression of OATP1A2 and OATP2B1.
Materials and methods

Antibodies
Polyclonal affinity-purified OATP1A2 and OATP2B1 were generated in rabbits and characterized as previously described [12, 13, 26, 36] . Guinea pig anti-substance P (SP) and sheep anti-vasoactive intestinal peptide (VIP) were purchased from Chemicon (Temecula, CA, USA). All secondary antibodies conjugated with either Cy2 or Cy3 fluorochrome or with biotin-horseradish peroxidase were purchased from Jackson ImmunoResearch (West Grove, PA, USA) and Santa Cruz (Santa Cruz, CA, USA), respectively. Brain [48] Brain capillary endothelial cells [53] , neurons, glial cells [2] Estrone-3-sulfate [22] OATP2B1 Protein expression in brain microcapillaries [32] n/a DHEAS, estrone-3-sulfate [22] OATP3A1 Brain [26] Neurons, choroid plexus epithelial cells [26] Estrone-3-sulfate [22] Rat rOATP1A1 Brain [31] Choroid plexus epithelial cells [3] DHEAS, estrone-3-sulfate [22] 
Brain [47] , choroid plexus [8] Brain capillary endothelial cells, choroid plexus epithelial cells [14] , retinal pigment epithelial cells [15, 28] , retinal capillary endothelial cells [1] DHEAS, estrone-3-sulfate, N-retinyl-N-retinylidene ethanolamine [22] rOATP1A5 Brain [66] choroid plexus [8] Retinal pigment epithelial cells, ganglion cells [28] , retinal capillary endothelial cells [1] DHEAS, estrone-3-sulfate [22] rOATP1C1 Brain [60] Brain capillary endothelial cells, choroid plexus epithelial cells [60] DHEAS, estrone-3-sulfate, DPDPE [22, 60] rOATP2B1 Brain [46] Brain capillary endothelial cells, choroid plexus epithelial cells [52] Prostaglandins [22] rOATP4A1 n/a Retinal pigment epithelial cells, ganglion cells [29] Triiodothyronine (T3) [22] For a comprehensive list of endogenous substrates, the reader is referred to [22] n/a not available 
Human tissue collections
Retinas were collected from four deceased patients of both genders (age range 25-88 years) during routine autopsies (postmortem periods 8-12 h) in the Department of Ophthalmology, University Hospital Zurich, according to a protocol approved by the local ethics committee. One of these retinas was used for immunoblot analysis, thus frozen immediately in liquid nitrogen upon dissection. The other retinas were fixed as described below for immunofluorescence staining experiments. Human 5 μm brain sections embedded in paraffin were provided by the Department of Neuropathology, University Hospital Zurich. They were cut from the frontal cerebral cortex and the hippocampal formation. These specimens were from two patients (both genders, aged 39 and 79 years old) without evidence of neurological or psychiatric disorders and with normal brain morphology. The postmortem intervals were 30-48 h. The blocks of the specimens were fixed routinely with formalin after removal during autopsy.
Immunoblot analysis
The isolated human retina was processed as described in [15] . In brief, it was homogenized in 100 mM Tris pH 7.5 with a tip sonicator, and the homogenates were centrifuged at 1,000×g for 5 min to remove large debris. Protein content of the supernatant was assessed by the Bradford assay (BioRad, Hercules, CA) using BSA as standard. The supernatant was mixed with SDS sample buffer, heated to 70°C for 10 min, and stored at −20°C until use. Proteins were separated on 7.5 % SDS-polyacrylamide gels and processed as described in [15] .
Immunofluorescence staining
Dissected retinas were fixed in phosphate-buffered saline (PBS) containing 3 % (w/v) paraformaldehyde and 0.1 % (w/v) glutaraldehyde (pH 7.4) at 4°C for 2 h, cryoprotected in 30 % (w/v) sucrose overnight at 4°C, embedded in M1-embedding matrix (Lipshaw, Pittsburg, PA, USA), and stored at −70°C until use.
Ten micrometer vertical cryostat sections were cut and mounted on glass slides coated with 0.5 % gelatin and incubated with primary antibodies in PBS containing 2 % (v/v) normal goat serum and 0.2 % (w/v) Triton X-100 overnight at 4°C. The dilution for OATP1A2 was 3 μg/ml and for OATP2B1 1 μg/ml. The protocol for antibody visualization is detailed in [15] . For double staining experiments, sections were coincubated with one of the OATP antibodies with either anti-SP or anti-VIP. The signal for OATP1A2 and OATP2B1 was detected with the Cy3-conjugated goat anti-rabbit antibody (1:300), and for SP and VIP, it was detected with a Cy2-conjugated goat antibody against corresponding species.
Immunoperoxidase staining Human brain sections were processed according to a previously developed protocol [26] . After dewaxing and rehydrating the paraffin sections, these were treated with 0.1 M hydrochloride acid for 10 min, 0.1 % (w/v) saponin in PBS for 30 min, and finally with 1.5 % (w/v) hydrogen peroxide for 10 min to eliminate endogenous peroxidase activity. For antigen retrieval, sections were immersed in 0.2 M citric acid (pH 4.5) and heated three times to 80°C for 5 min in a microwave processor. In the initial experiments, sections were heated one, three, and five times in order to optimize detection, and three times of microwave radiation was found suitable for the present study (data not shown). Afterward, sections were incubated overnight at 4°C with antibodies to OATP1A2 (10 μg/ml) or OATP2B1 (3 μg/ml) diluted in 50 mM Tris/100 mM NaCl (Tris-saline, pH 7.4) containing 2 % (w/v) normal goat serum and 0.05 % (w/v) Triton X-100. They were washed in Tris-saline and stained by the ABC-immunoperoxidase method with Vectastain Elite kit (Vector Laboratories, Burlingame, CA, USA) and diaminobenzidine hydrochloride as chromogen. Finally, the sections were dehydrated with ascending series of ethanol and coverslipped out of xylene. For negative controls, the primary antibodies were preabsorbed with 5-10 mg/ml of corresponding peptides used for immunization. After processing, sections were analyzed by confocal laser microscopy (MRC 600 Confocal Imaging System, BioRad Laboratories, Richmont, CA) using a Zeiss Axioplan microscope (Oberkochen, Germany).
Transport assays in Xenopus laevis oocytes Mature X. laevis females were purchased from the African Xenopus facility (Noordhoek, Republic of South Africa) and kept under standard conditions. The animals received human care according to federal and local regulations, and the experiments were approved by the local government's animal care committee. In vitro synthesis of complementary RNAs (cRNAs) for OATP1A2 [35] and OATP2B1 [36] was performed from the respective cDNAs as described [36] .
Oocytes were prepared as previously described [50] . Healthy oocytes were microinjected with either water (control) or 5 ng of cRNA encoding OATP1A2 or OATP2B1. The oocytes were cultured for 3 days to allow expression of the transporter proteins. Tracer uptake experiments were carried out in the presence of Na + (100 mM NaCl) or absence of Na + (100 mM choline chloride) in uptake media containing 2 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , and 10 mM HEPES/Tris (pH 7.5) as detailed in [37] . Statistical significance was calculated with the unpaired Student's t test (Systat, SPSS, Chicago, IL). K m values were estimated by nonlinear regression analysis using the Michaelis-Menten model with Systat.
Results
Expression of the OATP1A2 and OATP2B1 immunoreactivity in the human retina
Immunofluorescence microscopy analysis of retina sections demonstrated that both antibodies displayed strong reactivity (Figs. 1a and 2a) . Surprisingly, however, no immunoreactivity was observed in the apical region of the retina pigment epithelium, the site at which rOATP1A4 immunoreactivity is located in rat retina [15] . OATP1A2 immunoreactivity appeared broadly in many retina cell layers, including the outer nuclear layer (ONL), inner nuclear layer (INL), inner Fig. 1 Expression of OATP1A2 in human retina. a Overview of immunolabeling at low magnification shows strong immunoreactivity for OATP1A2 in the outer nuclear layer (ONL), inner nuclear layer (INL), and ganglion cell layer (GCL) and weak labeling of the inner plexiform laer (IPL). b Negative control with preabsorption of the antibody with the immunizing peptide displays some autofluorescence in the retina pigment epithelium (RPE). c High magnification centered on the ONL show plasma membrane labeling of retina photoreceptor bodies. Scale bar=60 μm. d Corresponding differential interference contrast (DIC) image to c. Scale bar=12 μm. e High magnification of the IPL demonstrates immunoreactivity of INL, IPL, and GCL. Note that stained amacrine cells (marked with asterisks) extend their heavily labeled processes to the IPL and GCL. f Corresponding DIC image to e. Scale bar= 10 μm plexiform layer (IPL), and the ganglion cell layer (GCL) (Fig. 1a) . At high magnification, the staining in the ONL was seen at the plasma membrane of photoreceptor bodies (Fig. 1c) . In the INL, OATP1A2 immunoreactivity was abundant in many cell somas that are lying in the innermost part of the layer, resembling amacrine neurons. These cells were often seen to extend their strongly stained processes into the IPL and GCL (Fig. 1e) . In the GCL, a few small cells were also stained, whereas large ganglion cells appeared negative (Figs. 1e and 6a ). For OATP2B1, the staining was rather restricted to the innermost part of the INL and in the IPL (Fig. 2a) . At high magnification, the OATP2B1-IR in the INL was present in proximal processes of amacrine cells but sparsely in their somas (Figs. 2c, 6b, and 7b ). In the IPL, numerous neuronal processes were stained, forming a dense plexus of OATP2B1 immunoreactivity throughout the entire layer (Fig. 2a, c) .
In the control experiments in which adjacent sections were incubated with antibodies preabsorbed with the corresponding peptide antigens used for immunization, no positive signals were detected (Figs. 1b and 2b) , whereby the faint reaction in the RPE is due to autofluorescence of the tissue. Western blot experiments were carried out to further confirm the presence of OATP1A2 and OATP2B1 proteins in the retina. As illustrated in Fig. 3 , both antibodies reacted specifically with retina homogenates. OATP1A2 and OATP2B1 proteins in the retina appear to have a similar size (~70-80 kDa) to those identified in the human brain [12] and ciliary body [13] as well as human liver [36] and placenta [56] as well as after heterologous expression [26] . As observed earlier, both OATPs appeared as a double band on the Western blots (Fig. 3, lanes 1 and 3) . Thereby, the band with the lower MW most likely corresponds to the nonglycosylated protein [12] .
OATP1A2-and OATP2B1-mediated transport activities of bioactive peptides in X. laevis oocytes The findings that OATP1A2 and OATP2B1 are present in the retina amacrine neurons prompted us to assume that these transporters may play a role in mediating transport of some neuronal messengers, such as neurotransmitters or neuroactive peptides. While previous data have indicated that neurotransmitters, such as GABA, glutamine, and serotonin, are most likely not substrates of rat OATPs [47] , it is not clear, however, whether this assumption also holds true for human OATPs. Human amacrine neurons are known for containing several neurotransmitters such as GABA, dopamine, glycine, and glutamate [9, 49] and many bioactive peptides, including SP, VIP, somatostatin (SOM), and NPY [10, 38, 45, 57, 63] . To corroborate our hypothesis that OATP1A2 and OATP2B1 may mediate transport of some of the neuroactive substances, functional transport assays were performed in OATPexpressing oocytes. Not surprisingly, no transport activities were found for neurotransmitters GABA, glutamate, glycine, and dopamine (not shown) in these experiments. However, compared with water-injected oocytes, OATP1A2-and OATP2B1-expressing oocytes exhibited two-to threefold uptake signals for SP and VIP, but not for SOM and NPY (Fig. 4) . Further analysis indicated that OATP1A2-and OATP2B1-mediated uptake for SP and VIP was sodiumindependent (Fig. 4a, b) and saturable with apparent K m values of 76 and 73 μM for OATP1A2-mediated SP and VIP uptake and 84 and 94 μM for OATP2B1-mediated SP and VIP uptake, respectively (Fig. 5) .
Expression of the OATP1A2-and OATP2B1-IR in retina SPand VIP-containing neurons
It is well known that neurotransmitter transporters are often expressed in the same neurons that release corresponding neurotransmitters in order to take up again released neurotransmitters back into neurons. Since OATP1A2 and OATP2B1 exhibit transport activities for SP and VIP, we investigated whether OATP1A2 and OATP2B1 are expressed in subpopulations of amacrine cells that contain SP and VIP [10, 38, 63] . Double fluorescence staining experiments with antibodies against OATPs and against SP and VIP showed extensive colocalization of OATP1A2 immunoreactivity with SP labeling, both in amacrine cell somas in the INL and in neurites of the IPL and GCL (Fig. 6c) . A few SP-containing cells in GCL, previously identified as SP-containing amacrine cells [5, 23, 70] , were also labeled with OATP1A2 Fig. 6e, f) . OATP1A2 immunoreactivity was also colocalized with VIP fluorescence, particularly in the small cells and neurites in the GCL, but less in the IPL and INL (Fig. 6i) . OATP2B1 immunoreactivity was, although to a lesser extent, also colocalized with SP labeling, especially at neuronal processes in the IPL (Fig. 7c, f) . When the OATP2B1 antibody was coincubated with the VIP antibody, the OATP2B1 immunoreactive neuronal processes were intensely colocalized with VIP fluorescence (Fig. 7i) .
In addition, to clarify whether the abundant OATP immunoreactivity in the GCL (Fig. 1a) is also present in retinal macroglial cells (astrocytes and Müller cells) localized in this layer [68] , double staining experiments were performed in which the anti-OATP1A2 antibody was coincubated with an anti-glial fibrillary acidic protein, a glial marker. No Localization of OATP1A2 and OATP2B1 in the human frontal cortex and hippocampus
Expression of OATP1A2 and OATP2B1 in the retina neurons raises the possibility that the two OATPs may be also expressed in brain neurons. We have previously detected a weak, but distinct expression of the OATP1A2 immunoreactivity in brain capillary endothelial cells on fresh cryostat sections of the cerebral cortex [12] , while on Northern blots, OATP1A2 is abundantly expressed in human brain [35] . Mildly fixed cryostat sections, although perhaps good for detection of some antigens, usually have poorly preserved the plasma membrane structure, thus may not be very suitable for recognizing proteins associated with neuronal processes.
In the present study, we used paraffin-embedded sections and applied a microwave antigen retrieval protocol. With this protocol, OATP1A2 was found to be abundantly expressed in neurons in both cortex and hippocampus (Figs. 8 and 9 ). As illustrated in Fig. 8a , in the frontal cortex, neurons scattered all layers were labeled with the OATP1A2 immunoreactivity. In the hippocampal formation, shown in Fig. 9 , pyramidal neurons in the CA1 and CA2 regions and granule cells in the dentate gyrus were also strongly labeled. Under high magnification, the OATP1A2 immunoreactivity was associated with the plasma membrane of cell somas and with neuronal processes (Figs. 8c and 9b, c) . Consistent with the previous finding [12] , OATP1A2 immunoreactivity was also occasionally found in capillary endothelial cells (Fig. 8a, c) in the paraffin sections used for this study. Surprisingly though, the OATP2B1 immunoreactivity was distinctly associated with brain capillary endothelial cells (Fig. 10) The close-up of the CA2 region shows OATP1A2 immunopositivity in numerous pyramidal neurons and their processes. c OATP1A2 immunoreactivity is predominantly present in the plasma membrane of granule cell somas and neuronal processes in the stratum moleculare of the dentate gyrus (SM). Scale bar=37 μm endothelium under high magnification (Fig. 10c) . OATP2B1 immunoreactivity-associated endothelial cells were numerous in both the cortex and hippocampus. The abundant expression of OATP2B1 in capillary endothelial cells suggests that this transporter plays an important role at the blood-brain barrier (BBB).
Discussion
The data presented here show that (1) OATP1A2 and OATP2B1 are abundantly expressed in retina SP-and VIPcontaining amacrine neurons and their processes; (2) OATP1A2 and OATP2B1 exhibit similar transport activities for SP and VIP when expressed in X. laevis oocytes; and (3) in the cerebral cortex and hippocampal formation, OATP1A2 is predominantly present in various types of neurons and OATP2B1 is exclusively present in the blood-brain barrier.
The diversity of cellular distribution of OATP1A2 and OATP2B1 in the CNS is somewhat surprising. This diversity is reflected not only in different cell types but also in various types of neurons with distinct neurotransmitter phenotypes. For example, OATP2B1 in retina is distinctly present in amacrine neurons (Fig. 2) , whereas in the brain, it localizes to the capillary endothelium (Fig. 10) . OATP1A2 is expressed in amacrine cells (Fig. 1 ) that contain inhibitory neurotransmitters, e.g., GABA [9] , and also in neurons containing the excitatory neurotransmitter glutamate, such as photoreceptor cells and hippocampal pyramidal and granule cells [4, 9] . It was previously noted in rat that the retina utilizes different mechanisms from the brain for regulating the expression of transporters. For example, the glycine transporter rGLYT-1 is expressed in glial cells of rat brain and in amacrine cells in the retina [69] . In humans, GLYT-1 expression is absent in Müller cells of intact retina but present in cultured Müller cells [51] . Similarly, while the glutamate transporter GLT-1 is located in the brain in glial cells, it is found in neurons of the retina [61] . So far, the knowledge about factors involved in determining the differential cellular expression of such transporters is still in its infancy [16, 51] . Our findings of the OATP2B1 localization to distinct cells in the brain and retina are another example of differential regulation of transporter expression in the CNS [51] . The highly heterogeneous cellular distribution and their multispecific transport properties [20] indicate complex functions of OATP1A2 and OATP2B1 in the CNS.
In the present study, we have identified the neuropeptides SP (11 amino acids) and VIP (28 amino acids) as substrates of OATP1A2 and OATP2B1. This result is not unexpected since rOATPs/OATPs seem to have preferences for small peptides with 10-20 amino acids [20] . Our data while strongly indicating that OATPs function as peptide uptake systems in the CNS as do they do for example in the liver [27] or across the BBB [12] may also leave open other interpretations. Neuropeptides, stored in synaptic vesicles, are often released together with neurotransmitters by presynaptic neurons. Unlike neurotransmitters that are mostly recycled back to neurons by their corresponding transporters, elimination of neuroactive peptides from the synaptic cleft is generally thought by diffusion and, more importantly, by degradation with peptidases. Of the several enzymes that are involved in metabolizing SP and VIP [7, 25, 42] , neutral endopeptidase (NEP, EC 3.4.24.11) appears to play a predominant role in the brain [17, 18, 24, 25, 43, 64] . This enzyme is abundantly present in the striatonigral pathway but scarcely, if at all, in the cerebral cortex (100 vs. 4 %) [43] . Thus, NEP distribution seems to be only matched, notably in striatonigral pathway, with that of SP, but not in the cerebral cortex where both SPand VIP-containing neurons and their processes are abundantly located [39, 40] . This only partially matched distribution pattern was also demonstrated in a detailed immunohistochemistry analysis [44] . There is no report so far, to our knowledge, on the presence of NEP in the retina. Another peptidase angiotensin-converting enzyme (3.4.15.1) is also suggested to be involved in inactivation of SP in the brain [25, 59] . It has a very low capacity compared to that of NEP [25] and is also mainly present in the striatonigral pathway [59] . In the retina, the angiotensin-converting enzyme was only detected in chicken after pretreatment with protease inhibitors [67] , but not in the rat [58] , suggesting at best a low expression level in this tissue. Taken together, the partially matched distribution pattern raises a possibility that alternative mechanism(s) may be involved in determining turning over the released neuroactive peptides in the synaptic cleft, particularly in areas that are short of degrading enzymes but rich in peptides, such as the cerebral cortex [39, 40, 55] and retina. Our findings that OATP1A2 and OAPT2B1 are abundantly present in the cerebral cortex and retina and that they exhibit saturable transport activity for SP and VIP argue for a functional role of these OATPs in clearing released neuropeptides. Their rather low affinities (K m~7 0-100 μM) for these peptides appear to be in agreement with the generally prolonged actions of neuroactive peptides. Moreover, expression of these transporters in peptide-containing neurons (Figs. 6 and 7) suggests that these transporters may reuptake these neuroactive peptides back to the neurons as do neurotransmitter transporters. In this context, it is interesting to note that the amacrine cell of the retina is a special type of nerve cell as it lacks an axon and it has its dendrites functioning as axons. Extensive expression of OATP1A2 and OATP2B1 in peptidecontaining processes in the IPL (Figs. 6 and 7) thus suggests that uptake activity, at least in the retina, may occur at peptidereleasing sites.
OATP1A2 and OATP2B1 may also mediate transport of other neuroactive substances in the CNS, as suggested by their broad substrate specificity and diverse cellular expression pattern (Table 1) . Of these, neurosteriods and their sulfate conjugates are of particular interest. OATP1A2 exhibits a very high transport activity for dehydroepiandrosterone sulfate (DHEAS, K m~6 μM) and estrone-3-sulfate (E3S) [34, 36] . For OATP2B1, these two steroids, together with pregnenolone sulfate (PREGS) [19] , are essentially the only natural substrates identified so far [20] . Some steroids, such as pregnenolone, dehydroepianderosterone (DHEA), and 17-β-estradiol (both unsulfated and sulfated forms), can modulate neurotransmission by acting directly on neurotransmitter receptors such as NMDA and GABA receptors on the cell surface, thus functioning as an important group of neuromessengers and, hence, exert nongenomic effects [54] , e.g., inhibition of GABA A receptors by DHEA or DHEAS may be neuroprotective [41] . In addition to modulating receptors, DHEAS may affect the transcription of tyrosine hydroxylase and/or modulate actin depolymerization in neuronal cells [41] , requiring the presence of DHEAS in the cytoplasms. DHEA and DHEAS are the most abundant steroid hormones in humans, and while it was earlier assumed that brain DHEAS originates from the adrenal cortex, it is now accepted that DHEA and DHEAS are also synthesized in the brain [11] . Hence, it is tempting to speculate that OATP1A2 as well as OATP2B1 may, at the site of their expression, mediate cellular uptake of DHEAS. Moreover, since rOATP/OATP-mediated transport appears to be bidirectional [37] , OATP2A1 may also play a role in the reuptake of these substances back to the cell and OATP2B1 in delivering blood-borne steroids to target sites.
In conclusion, our data suggest that OATP1A2 and OATP2B1 are involved in mediating transport of neuropeptides and neurosteroids across the plasma membrane of neurons and capillary endothelium. Further characterization of these transporters in vivo is essential to clarify the data from the present study. Furthermore, the significance of these OATPs in mediating the transport of other endogenous substances including prostaglandins and in bioavailability and disposition of drugs in the CNS needs to be explored in the future.
